Relationship between acute urinary retention and intraprostatic inflammation in benign prostatic hyperplasia

Korean Journal of Urology

Volumn 49, Issue 12, 2008, Pages 1081-1086

  Ha, Ji Yong ^a   Kwak, Dong Yun ^a   Chang, Hyuk Soo ^a   Park, Choal Hee ^a   Kwon, Sun Young ^a   Kim, Chun Il ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Prostatic hyperplasia; Prostatitis; Urinary retention

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACUTE URINARY RETENTION; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INTRAPROSTATIC INFLAMMATION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RISK FACTOR; TRANSURETHRAL RESECTION; URINE RETENTION;

EID: 58149296010     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2008.49.12.1081     Document Type: Article

References (30)

1. Emberton M, Anson K. Acute urinary retention in men: an age old problem. BMJ 1999;318:921-5
2. Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol 2002;42:329-32
3. Kefi A, Koseoglu H, Celebi I, Yorukoglu K, Esen A. Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen. Scand J Urol Nephrol 2006;40:155-60
4. Tuncel A, Uzun B, Eruyar T, Karabulut E, Seckin S, Atan A. Do prostatic infarction, prostatic inflammation and prostate morphology play a role in acute urinary retention? Eur Urol 2005;48:277-83
5. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim OM, et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007;100:327-31
6. Kim MJ, Lee JG, Cheon J. The factors that influence the success rate of treatment without using a catheter for the management of acute urinary retention: comparison of in-and-out catheterization and Foley indwelling catheterization. Korean J Urol 2008;49:337-42
7. Chang HS, Park CH, Kim CI. Transitional zone volume: a predictor of acute urinary retention in patients with benign prostatic hyperplasia. Korean J Urol 2005;46:259-63
8. Lee SJ, Kim YT, Lee TY, Woo YN, Analysis of risk factors for acute urinary retention after non-urogenital surgery. Korean J Urol 2007;48:1277-84
9. Irani J, Levillain P, Goujon JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997;157:1301-3
10. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, et al. Evaluation of prostatitis in autopsied prostates - Is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179:1736-40
11. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-7
12. Kurita Y, Masuda H, Terada H, Suzuki K, Fujita K. Transition zone index as a risk factor for acute urinary retention in benign prostatic hyperplasia. Urology 1998;51:595-600
13. Kim JH, Kim HG, Park WH. The predictors of acute urinary retention in patients with benign prostatic hyperplasia. Korean J Urol 2002;43:949-55
14. Fowler FJ Jr, Wennberg JE, Timothy RP, Barry MJ, Mulley AG Jr, Hanley D. Symptom status and quality of life following prostatectomy. JAMA 1988;259:3018-22
15. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7
16. Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999;53:473-80
17. Kim CI, Chang HS, Kim BK, Park CH. Long-term results of medical treatment in benign prostatic hyperplasia. Urology 2006;68:1015-9
18. Lynch TH. Doxazosin and finasteride alone or in combination: the PREDICT study. BJU Int 2003;91:591-2
19. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
20. Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol 2003;43:164-75
21. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology 1998;51:578-84
22. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol 2002;168:2467-71
23. Roehrborn CG, Kaplan SA, Noble WD, Slawin KM, McVary KT, Kusek JW. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH. Results from the MTOPS study. J Urol 2005;173(Suppl):346, abstract 1277
24. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;2(Suppl):33-50
25. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-81
26. Collins MM, Meigs JB, Barry MJ, Walker Corkery E, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002;167:1363-6
27. Kramer G, Marberger M. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006;16:25-9
28. Andriole G, Bostwick D, Brawley O, Gomella L, Margerger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172:1314-7
29. Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am 2008;35:109-15
30. Minnery CH, Getzenberg RH, Robert H. Benign prostatic hyperplasia cell line viability and modulation of JM-27 by doxazosin and ibuprofen. J Urol 2005;174:375-9